耐药细菌感染的不断蔓延对公共卫生安全构成重要威胁,早期诊断和目标治疗是治疗成功的关键。传统细菌培养及药物敏感性检测耗时长、敏感性不高,无法满足临床诊治需求,高通量测序等分子检测技术成为新的发展方向。本文对近年来有关高通量测序在革兰阴性菌耐药诊治中的进展做一综述。
The ongoing spread of drug-resistant bacterial infections poses a significant threat to public health, and early diagnosis and targeted treatment are the keys to successful treatment. Traditional bacterial culture and drug susceptibility testing is time-consuming and insensitive, and cannot meet the needs of clinical diagnosis and treatment, so molecular detection technologies, such as metagenomics next-generation sequencing, have become a new research direction. This article reviewed recent advances in high-throughput sequencing for the diagnosis and treatment of drug resistance in Gram-negative bacteria.
梁文炎,施毅,孙文逵. 宏基因组高通量测序技术在革兰阴性菌耐药表型检测中的研究进展[J]. 中华结核和呼吸杂志,2022,45(02):209-213.
DOI:10.3760/cma.j.cn112147-20210705-00468版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
梁文炎, 施毅, 孙文逵. 宏基因组高通量测序技术在革兰阴性菌耐药表型检测中的研究进展[J]. 中华结核和呼吸杂志, 2022, 45(2): 209-213. DOI: 10.3760/cma.j.cn112147-20210705-00468.

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。